Wednesday, January 13, 2021
Ketamine is often thought of as an illicit party drug — something people take for a momentary high. But it wasn’t designed to be a mind-altering drug. Originally, ketamine was developed as anesthetic to relieve temporary pain. And now it seems the drug can provide solace not just from physical distress. At the NIH, Dr. Carlos Zarate is investigating how ketamine can rapidly reduce depressive symptoms in people with treatment-resistant depression or bipolar depression, for whom other options have not helped.
Thursday, October 22, 2020
In nature, strategic alliances can mean the difference between life and death. For humans, such vital partnerships exist between us and the trillions of microbes we unwittingly host in and on our bodies - together called the microbiome. Dr. Heidi Kong uses genomics to uncover the microbe-host interactions taking place all over our skin. Building on her work and a growing understanding of the skin microbiome, Dr. Ian Myles has developed a bacterial spray that improves eczema, an inflammatory skin disease.
Thursday, September 3, 2020
Dr. Peter Bandettini spends a lot of time peering into people's heads. Not because he is clairvoyant, but because he is a biophysicist. Using functional MRI (fMRI), a revolutionary neuroimaging technique he helped pioneer in the '90s, Dr. Bandettini delves into the mysteries of the human brain. He is working to advance fMRI technology to parse out more information about the neural connections that are constantly and spontaneously active even when we think our minds are blank.
Thursday, August 6, 2020
Time and again, diversity and inclusion initiatives have proven to boost productivity and overall well-being in the workplace. But despite countless studies and although there have been significant strides in recent history, the struggle to ensure equal opportunity persists. At the NIH, the Scientific Workforce Diversity (SWD) Office is expanding recruitment and retention with Dr. Hannah Valantine as its first chief officer. She emphasizes how proper resources, mentorship, and community are essential for progress in the biomedical field.
Thursday, June 25, 2020
In this episode, Dr. Richard Childs, a senior investigator and Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI), recounts his experience using the antiviral remdesivir to treat patients with COVID-19 in one of the early hot zones of the pandemic. He led a team sent to care for passengers on the Diamond Princess cruise ship that was held in quarantine in Yokohama, Japan at the start of the outbreak. Since then, remdesivir has continued to gain traction as a possible standard of care. Dr. Matthew Hall, biology group leader at the National Center for Advancing Translational Sciences (NCATS), explains the development of the drug and its newfound purpose in the battle against the novel coronavirus.
Thursday, May 21, 2020
Perhaps now more than ever, it is undeniable how integral vaccines have become to public health. Vaccines protect us from a whole host of infectious diseases, including chickenpox, measles and the seasonal flu. With a new threat at hand, scientists at the NIH swiftly developed a vaccine candidate against the novel coronavirus that causes COVID-19. The pre-clinical effort was driven in part by Dr. Kizzmekia Corbett, a viral immunologist and research fellow in the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID).
Wednesday, April 15, 2020
Social distancing is the best way to curtail the spread of COVID-19, but if innumerable days of isolation start to feel like they’re taking a toll on your mental welfare, there might be some solace waiting in the kitchen. According to mental health experts, cooking can reduce anxiety and alleviate mental distress. Dr. Nicole Farmer is a clinical researcher studying many facets of how diet affects human biology and behavior, including the effects of cooking interventions on mental well-being.
Monday, February 24, 2020
Radioactive drugs carry radioactive substances that can be engineered to specifically target and kill tumor cells inside the body. In 2018, the FDA approved a radioactive drug called Lutathera to treat tumors that affect the pancreas or gastrointestinal tract. Now, scientists at the NIH led by Dr. Frank Lin are testing whether Lutathera can also be effective against rare tumors of the adrenal glands. Dr. Lin is a clinician and researcher focused on bringing radioactive drugs — also known as radionuclides — from bench to bedside. His work could accelerate the development of new therapies for patients with rare cancers who have few or no other treatment options.
Monday, January 27, 2020
The neurons in our brains use both electrical and chemical signals to communicate. When those signals are not generated or interpreted correctly, serious problems can arise. Dr. Jerry Yakel is a neurobiologist studying acetylcholine receptors, which allow neurons to turn signals transmitted using the chemical acetylcholine into electrical messages. Because acetylcholine receptors are found on so many nerve cells, numerous neurological disorders can arise when they fail to work properly, including Alzheimer’s, Parkinson’s, and epilepsy. By studying these receptors, Dr. Yakel’s team hopes to better understand how they contribute to disease, which could eventually lead to therapies for a variety of neurological conditions.
Monday, December 9, 2019
Anybody who observes a person with a neurological illness like Tourette syndrome or schizophrenia can clearly see how these conditions affect behavior. What’s much more difficult to determine is how these ailments relate to changes in the brain. Dr. Armin Raznahan is a child psychiatrist who uses a genetics-first approach and state-of-the-art neuroimaging tools to examine how the size and shape of the brain differ in children and adolescents with neuropsychiatric disorders compared to healthy individuals. His discoveries about these illnesses could ultimately improve our ability to identify and treat people who have them, as well as predict which children might develop them.